Intravacc

Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

The Protein Brewery is a high-tech company that specializes in developing and making animal-free- based protein in a sustainable way. It's a spin-out from BioscienZ and is commercializing innovative protein production using fermentation. It was founded by Wim de Laat in 2019 and is based in Breda, Noord-Brabant, The Netherlands.

Revyve produces animal-free food ingredients from microorganisms. The company's premium ingredients include emulsifiers, heat-set gels, and foaming agents. It helps customers with special protein functionality requests.

Merus is dedicated to creating superior treatments for cancer patients and potentially finding a cure. Our most advanced research programs utilize the Biclonics® format, which have the unique ability to attack tumors in multiple ways. These Biclonics® can activate the immune system to eliminate tumor cells and directly hinder the growth and survival processes of these cells. Choosing to work at Merus means embarking on a career that offers personal and professional growth, as well as success for the company. By joining our team, you will contribute to the advancement of bispecific antibody therapies (Biclonics®) in the fight against cancer. Merus is headquartered in The Netherlands and has offices in the US, collaborating with partners around the globe. We have been listed on NASDAQ since 2016 and have several promising drugs in clinical trials spanning a decade. For more information, please visit our website at www.merus.nl. To ensure a positive community environment, we encourage you to review our Community Guidelines by visiting this link: https://merus.nl/community-guidelines/

Salvia BioElectronics is dedicated to creating new neuromodulation devices to help treat migraines. They are focused on developing a thin implant that can deliver gentle electrical pulses to nerves to reduce migraine symptoms. Through continued research and development, the company aims to advance its technology. With funding, they are working on bringing their migraine therapy to market to provide a different approach to pain management for patients, with a focus on improving patient outcomes using neuromodulation therapy.

We are a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, we are advancing our proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines. Our priority is to rapidly develop our pipeline to deliver transformative medicines for patients living with mitochondrial disease. Our in-house scientists are driving innovative research projects and building a portfolio of promising compounds. We have active discovery programmes underway developing new therapies, biomarkers, diagnostic applications and new read-out technologies in the field of mitochondrial diseases. Our lead pipeline asset, KH176, is a potential first-in-class oral small molecule in phase IIb clinical development to treat a range of mitochondrial diseases. It has been granted Orphan Drug Designation for MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders and Leigh disease in Europe and for all inherited mitochondrial respiratory chain disorders in the US. We work in collaboration with patient organisations internationally as well as a global clinical and academic network to accelerate the discovery and development of our potential medicines for patients with mitochondrial diseases

QurieGen is a biotechnology company that speeds up the process of finding and creating new drugs.

Protix Biosystems is a biometrics company that offers a range of products which enable its customers to optimize their feed solutions. It was founded in 2009 and is based in Dongen, the Netherlands.

QDI Systems is a startup company that engages in the development of advanced imaging devices for medical purposes, utilizing quantum dot technology for various applications. Their main value proposition is centered around providing user-friendly quantum dot material along with detailed instructions on how to create high-performance devices using it.

BIMINI Biotech, a startup established in 2019 in Leiden, The Netherlands, focuses on creating groundbreaking therapeutic approaches for oncology by targeting the growth hormone receptor (GHR) and its interaction with insulin-like growth factor 1 (IGF-1). The company also aims to address metabolic diseases and aging through its innovative strategies.

Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis. Citryll was established in 2015 and is headquartered in Oss, The Netherlands.

Alveron Pharma develops treatment for hemorrhagic stroke, a severe unmet medical need. Alveron’s drug OKL-1111 strongly reduces hematoma expansion in a mouse model of intracranial hemorrhage. As an injection solution that is ready to use, OKL-1111 is being developed to do away with a laborious pre-treatment process.